R Jayachandra Babu Selected Research

spantide II

10/2005	In vitro and in vivo evaluation of topical formulations of spantide II.
1/2004	Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R Jayachandra Babu Research Topics

Disease

9	Neoplasms (Cancer) 01/2022 - 01/2018
6	Inflammation (Inflammations) 01/2022 - 01/2004
5	Melanoma (Melanoma, Malignant) 05/2022 - 02/2019
3	Type 2 Diabetes Mellitus (MODY) 01/2018 - 11/2017
2	Wounds and Injuries (Trauma) 01/2020 - 01/2004
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2016 - 01/2004
2	Allergic Contact Dermatitis 10/2005 - 01/2004
1	Anterior Uveitis 07/2022
1	Pain (Aches) 01/2022
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Chronic Disease (Chronic Diseases) 12/2020
1	Stomach Neoplasms (Stomach Cancer) 09/2020
1	Hepatocellular Carcinoma (Hepatoma) 09/2020
1	Myeloid Leukemia (Leukemia, Myelocytic) 09/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Rheumatoid Arthritis 01/2020
1	Eye Diseases (Eye Disease) 08/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2019
1	Foreign Bodies (Foreign Body) 12/2018
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/2018
1	Dyslipidemias (Dyslipidemia) 01/2018
1	Alcoholic Fatty Liver 01/2018
1	Obesity 01/2018
1	Infections 07/2017
1	Skin Diseases (Skin Disease) 01/2015
1	Tachycardia (Tachyarrhythmias) 01/2008
1	Contact Dermatitis (Eczema, Contact) 01/2004

Drug/Important Bio-Agent (IBA)

10	Pharmaceutical PreparationsIBA 01/2022 - 07/2017
3	Liposomes (Liposome)IBA 05/2022 - 11/2020
2	difluprednate FDA Link 07/2022 - 01/2022
2	EmulsionsIBA 07/2022 - 01/2022
2	Small Interfering RNA (siRNA)IBA 01/2021 - 01/2015
2	LipidsIBA 01/2021 - 08/2019
2	hispolonIBA 11/2020 - 09/2020
2	SolutionsIBA 11/2020 - 01/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2020 - 02/2019
2	EnzymesIBA 01/2020 - 01/2018
2	CeramidesIBA 08/2019 - 02/2019
2	spantide IIIBA 10/2005 - 01/2004
1	Daunorubicin (Cerubidine)FDA LinkGeneric 05/2022
1	Isoflurophate (DFP)FDA Link 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	VaccinesIBA 06/2021
1	ResveratrolIBA 01/2021
1	AntibodiesIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Nucleic AcidsIBA 01/2021
1	PowdersIBA 12/2020
1	Dosage Forms (Dosage Form)IBA 12/2020
1	boswellic acidIBA 01/2020
1	FlavonoidsIBA 01/2020
1	tofacitinibIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	upadacitinibIBA 01/2020
1	MetalsIBA 01/2020
1	baricitinibIBA 01/2020
1	Janus Kinase InhibitorsIBA 01/2020
1	AcidsIBA 01/2020
1	SphingolipidsIBA 08/2019
1	thiazolyl blueIBA 02/2019
1	SuspensionsIBA 12/2018
1	EdaravoneIBA 11/2018
1	Riluzole FDA LinkGeneric 11/2018
1	Drug CarriersIBA 01/2018
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2018
1	GlucosidasesIBA 01/2018
1	Glycoside Hydrolase InhibitorsIBA 01/2018
1	voglibose (Basen)IBA 01/2018
1	miglitol (Glyset)FDA Link 01/2018
1	Acarbose FDA LinkGeneric 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 11/2017
1	SodiumIBA 11/2017
1	dalbavancinIBA 07/2017
1	Vancomycin FDA LinkGeneric 07/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2017
1	GlycopeptidesIBA 07/2017
1	Melanocortin Receptors (Melanocortin Receptor)IBA 01/2016
1	Ultrez 10IBA 01/2016
1	Melanocyte-Stimulating Hormones (MSH)IBA 01/2016
1	carboxypolymethyleneIBA 01/2016
1	Imiquimod (Aldara)FDA LinkGeneric 01/2016
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2008
1	Peptides (Polypeptides)IBA 01/2004
1	Substance PIBA 01/2004
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 01/2004
1	alpha-MSHIBA 01/2004

Therapy/Procedure

5	Therapeutics 01/2021 - 01/2015
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2021
1	Immunotherapy 01/2021